Co-Chairs of the trial.
The Spot sign and Tranexamic acid On Preventing ICH growth – AUStralasia Trial (STOP-AUST): Protocol of a phase II randomized, placebo-controlled, double-blind, multicenter trial
Article first published online: 26 AUG 2013
© 2013 The Authors. International Journal of Stroke © 2013 World Stroke Organization
International Journal of Stroke
Volume 9, Issue 4, pages 519–524, June 2014
How to Cite
Meretoja, A., Churilov, L., Campbell, B. C. V., Aviv, R. I., Yassi, N., Barras, C., Mitchell, P., Yan, B., Nandurkar, H., Bladin, C., Wijeratne, T., Spratt, N. J., Jannes, J., Sturm, J., Rupasinghe, J., Zavala, J., Lee, A., Kleinig, T., Markus, R., Delcourt, C., Mahant, N., Parsons, M. W., Levi, C., Anderson, C. S., Donnan, G. A. and Davis, S. M. (2014), The Spot sign and Tranexamic acid On Preventing ICH growth – AUStralasia Trial (STOP-AUST): Protocol of a phase II randomized, placebo-controlled, double-blind, multicenter trial. International Journal of Stroke, 9: 519–524. doi: 10.1111/ijs.12132
Conflicts of interest: Dr Meretoja has consulted for Boehringer Ingelheim. Dr Campbell has consulted for Lundbeck and received speaker's honoraria from Boehringer Ingelheim and Novartis. Dr Yan has received speaker's honoraria from Boehringer Ingelheim and educational grants from Bayer and CSL. Dr Nandurkar has consulted for Sanofi, Bayer, Pfizer, Alexion, GSK, and Hospira. Dr Sturm has received speaker's honoraria form Boehringer Ingelheim, Bayer, and Pfizer. Dr Markus has served on advisory board for Boehringer Ingelheim. Dr Levi served on advisory boards for Pfizer and Boehringer Ingelheim. Dr Donnan has consulted for Boehringer Ingelheim, Sanofi, Bayer, and Lundbeck. Dr Davis has served on advisory boards for Boehringer Ingelheim, Ever Pharma, and Sanofi-Aventis. He previously consulted for Novo Nordisk.
All other authors declare they have no conflicts of interest.
- Issue published online: 5 MAY 2014
- Article first published online: 26 AUG 2013
- Manuscript Accepted: 16 APR 2013
- Manuscript Received: 7 JAN 2013
- intracerebral hemorrhage;
- spot sign;
- tranexamic acid
No evidence-based acute therapies exist for intracerebral hemorrhage. Intracerebral hemorrhage growth is an important determinant of patient outcome. Tranexamic acid is known to reduce hemorrhage in other conditions.
The study aims to test the hypothesis that intracerebral hemorrhage patients selected with computed tomography angiography contrast extravasation ‘spot sign’ will have lower rates of hematoma growth when treated with intravenous tranexamic acid within 4·5-hours of stroke onset compared with placebo.
The Spot sign and Tranexamic acid On Preventing ICH growth – AUStralasia Trial is a multicenter, prospective, 1:1 randomized, double-blind, placebo-controlled, investigator-initiated, academic Phase II trial. Intracerebral hemorrhage patients fulfilling clinical criteria (e.g. Glasgow Coma Scale >7, intracerebral hemorrhage volume <70 ml, no identified secondary cause of intracerebral hemorrhage, no thrombotic events within the previous 12 months, no planned surgery) and demonstrating contrast extravasation on computed tomography angiography will receive either intravenous tranexamic acid 1 g 10-min bolus followed by 1 g eight-hour infusion or placebo. A second computed tomography will be performed at 24 ± 3 hours to evaluate intracerebral hemorrhage growth and patients followed up for three-months.
The primary outcome measure is presence of intracerebral hemorrhage growth by 24 ± 3 hours, defined as either >33% or >6 ml increase from baseline, and will be adjusted for baseline intracerebral hemorrhage volume. Secondary outcome measures include growth as a continuous measure, thromboembolic events, and the three-month modified Rankin Scale score.
This is the first trial to evaluate the efficacy of tranexamic acid in intracerebral hemorrhage patients selected based on an imaging biomarker of high likelihood of hematoma growth. The trial is registered as NCT01702636.